Smarticles Extend Their Reach in ProNAi's DNAi Approach
ProNAi Therapeutics Inc. became the second biotech to validate a savvy technology purchase by Marina Biotech Inc., extending its license for Marina's "Smarticles" liposomal delivery technology – used in its nucleic acid-based DNA interference (DNAi) therapies – from the clinic to potential commercialization.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST